|Other Names||Activin receptor type-2A, Activin receptor type IIA, ACTR-IIA, ACTRIIA, ACVR2A, ACVR2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7104a was selected from the Center region of human ACVR2A/B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A. Mediates induction of adipogenesis by GDF6 (By similarity).|
|Cellular Location||Membrane; Single-pass type I membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ACVR2A/B are activin A type II receptors. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases.
Jung, B., et al., Gastroenterology 126(3):654-659 (2004).Martins da Silva, S.J., et al., Dev. Biol. 266(2):334-345 (2004).Olaru, A., et al., Lab. Invest. 83(12):1867-1871 (2003).Casagrandi, D., et al., Mol. Hum. Reprod. 9(4):199-203 (2003).Greenwald, J., et al., Mol. Cell 11(3):605-617 (2003).
If you have any additional inquiries please email technical services at email@example.com.